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Dense Deposit Disease (DDD), or membranoproliferative
glomerulonephritis type II, is a rare renal disease
characterized by dense deposits in the mesangium and along
the glomerular basement membranes that can be seen by
electron microscopy. Although these deposits contain
complement factor C3, as determined by
immunofluorescence microscopy, their precise composition
remains unknown. To address this question, we used mass
spectrometry to identify the proteins in laser microdissected
glomeruli isolated from paraffin-embedded tissue of eight
confirmed cases of DDD. Compared to glomeruli from five
control patients, we found that all of the glomeruli from
patients with DDD contain components of the alternative
pathway and terminal complement complex. Factor C9 was
uniformly present as well as the two fluid-phase regulators of
terminal complement complex clusterin and vitronectin. In
contrast, in nine patients with immune complex–mediated
membranoproliferative glomerulonephritis, glomerular
samples contained mainly immunoglobulins and
complement factors C3 and C4. Our study shows that in
addition to fluid-phase dysregulation of the alternative
pathway, soluble components of the terminal complement
complex contribute to glomerular lesions found in DDD.
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Dense Deposit Disease (DDD, also known as membranopro-
liferative glomerulonephritis type II) is characterized by
thickening of glomerular basement membranes (GBMs) by
dense intramembranous deposits. The deposits are pathog-
nomic of this type of glomerulonephritis. They stain for C3 but
not immunoglobulins on immunofluorescence microscopy, but
otherwise lack substructure even by electron microscopy, which
resolves their presence in the mesangium and along GBMs.1,2
DDD is the result of dysregulation of the alternative
pathway (AP) of the complement cascade and secondary
persistent complement activation.3,4 This abnormal state is
reflected in the serum of affected patients by low C3 levels
and detectable C3 degradation products.5 One mechanism of
AP dysregulation in DDD is associated with the presence of
C3 nephritic factor, an autoantibody that stabilizes C3
convertase leading to C3 consumption and persistent AP
activation.6,7 DDD can also develop as a result of deficiency
of, or mutations in factor H, an essential serum protein for
AP control.3,4,8,9
Although immunofluorescence microscopy has confirmed
the presence of C3 in the dense deposits of DDD, their
composition otherwise remains unknown. In this study, we
have identified several additional proteins in the glomeruli of
patients with DDD by using laser capture microdissection
followed by liquid chromatography and mass spectrometry
(LCMS).
RESULTS
Patient characteristics and renal biopsy results
Renal biopsies from eight patients ranging in age from 11 to
49 years and diagnosed with DDD were selected for this
study. Nephrotic range proteinuria was present in three of
seven patients; in one patient, the extent of proteinuria
was not known. Five patients had stable renal function.
Complement factors C3 and C4 were low in most cases
(Table 1).
Renal biopsy revealed a membranoproliferative pattern of
injury on light microscopy (Table 2). The glomeruli were
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2009 International Society of Nephrology
Received 21 July 2008; revised 30 September 2008; accepted 4
November 2008; published online 28 January 2009
Correspondence: Sanjeev Sethi, Department of Laboratory Medicine and
Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.
E-mail: sethi.sanjeev@mayo.edu
952 Kidney International (2009) 75, 952–960
enlarged and showed mesangial expansion with increased
mesangial cellularity. Segmental endocapillary proliferation
was noted. The glomerular capillary walls were thickened,
and many loops showed cellular interposition and new
basement membrane formation resulting in double contours.
Six biopsies showed secondary focal and segmental glomer-
ulosclerosis. Four biopsies showed no or minimal tubuloin-
terstitial scarring (o10%); two cases showed moderate
tubulointerstitial scarring (approximately 20–25%); and two
cases showed extensive tubulointerstitial scarring (450%).
All cases showed C3 deposition in the mesangium and
along the glomerular capillary walls on immunofluorescence
microscopy, while staining for IgG, IgM, IgA, kappa, and
lambda light chains was negative. Electron microscopy
showed the typical electron dense deposits in the mesangium
and along the GBMs. Figure 1 shows representative light
microscopy (Figure 1a), immunofluorescence (Figure 1b),
and electron microscopy (Figure 1c) findings.
Control tissue was obtained from five cases of Day 0
transplant protocol biopsies. All cases were from living
donors. The glomeruli and interstitium were well preserved
and there was no significant scarring.
Laser microdissection of glomeruli
Preserved glomeruli (2 glomeruli per slide, 2 slides per case)
were microdissected. Although more cases were available, the
presence of extensive global glomerulosclerosis precluded
their use. Only cases with a membranoproliferative pattern of
injury were selected for LCMS studies. A representative
glomerulus is shown in Figure 2. Figure 2a shows the marked
glomerulus to be microdissected, and 2b shows the vacant
area in the glomerulus after microdissection. Each small
circle in the vacant area in the glomerulus represents one
laser shot used to transfer the cut tissue into the tube cap.
Figure 2c shows fragments of the glomerulus in the
microcentrifuge tube caps.
Protein identification via mass spectrometry
A typical Scaffold readout following LCMS from Case 4 is
shown in Figure 3a. Forty-five proteins were identified in the
microdissection sample (40–60 proteins are typically identi-
fied per microdissection sample). Several proteins of interest
are highlighted with a yellow star. Complement precursors to
C3, C5, C8a, and C9 were present with 100% probability, as
were complement factor H-related protein 1 (FHR1),
vitronectin, and apolipoprotein E (apoE). The first 2 columns
(highlighted in green) show the samples in duplicate
(microdissection 1 and microdissection 2). Immunostain
PID004S1 represents microdissection 1, and immunostain
PID004S2 represents microdissection 2. The next 2 columns
represent blanks post and pre run. They typically do not
contain any proteins but may show a little carryover (in this
case C3a and FHR1). A typical protein identification pattern
is shown in Figure 3b. In Case 4, there is a 6-peptide match
for precursor to C5.
In the Scaffold readout from all eight cases of DDD, we
identified components of the AP and terminal complement
complex (TCC) in nearly all dissected glomeruli. C9 was
uniformly present, as were clusterin and vitronectin, two
fluid-phase regulators of the TCC. FHR1 was seen in all DDD
Table 1 | Clinical features and laboratory values of Dense Deposit Disease patients
Patient




(mg/100 ml) C3 (70–150 mg/100 ml) C4 (14–40 mg/100 ml) Urinalysis
1 11 years, male 4.8 g 0.5 12 32 3+ protein, 1+ blood
2 15 years, female — 0.9 — — 3+ protein, 3+ blood
3 41 years, male 1.4 g 3.6 21 108 3+ protein, 2+ blood
4 15 years, male 0.500 g 1.0 19 — 4+ blood
5 18 years, female 7.7 g 0.7 13 22 3+ protein, 2+ blood
6 25 years, male 0.966 g 0.8 — — 3+ protein, 2+ blood
7 20 years, male 2.7 g 3.3 68 24 3+ protein, 2+ blood
8 49 years, female 7 g 3.5 6 22 3+ protein, 1+ blood
Table 2 | Renal biopsy results of Dense Deposit Disease patients
Patient no. Glomerular pathology Secondary findings Crescents/necrosis Interstitial scarring
1 Membranoproliferative glomerulonephritis FSGS None 10%
2 Membranoproliferative glomerulonephritis FSGS None 10%
3 Membranoproliferative glomerulonephritis FSGS None 20%
4 Membranoproliferative glomerulonephritis ATN None 25%
5 Membranoproliferative glomerulonephritis FSGS None 0
6 Membranoproliferative glomerulonephritis — None 0
7 Membranoproliferative glomerulonephritis FSGS None 60%
8 Membranoproliferative glomerulonephritis FSGS None 60%
ATN, acute tubular necrosis; FSGS, focal and segmental glomerulosclerosis.
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glomeruli and FHR5, another member of the factor H-related
gene family, was seen in two. ApoE was also always identified
(Table 3). Protein identification by LCMS of normal
glomeruli did not reveal any of the above listed proteins in
any case. A representative control and all DDD readouts are
shown in Figure 3c.
Figure 1 | Representative light, immunofluorescence, and electron microscopy in a case of Dense Deposit Disease. (a) Periodic acid
schiff (PAS)–stained section showing a membranoproliferative glomerulonephritis pattern of Dense Deposit Disease;
(b) Immunofluorescence microscopy with C3 deposition in the mesangium and along glomerular capillary walls; (c) Electron microscopy
resolving dense deposits in the mesangium and along the glomerular basement membranes (arrows).
Figure 2 | Laser microdissection of a glomerulus. (a) Glomerulus to be microdissected; (b) Vacant space on slide following
microdissection; (c) Fragments of the microdissected glomerulus in the microcentrifuge tube cap.
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Immune complex-mediated membranoproliferative
glomerulonephritis
For comparison, we completed LCMS protein identification
on nine cases of immune complex-mediated membranopro-
liferative glomerulonephritis (IC-MPGN). Included were
biopsies of idiopathic MPGN type I and MPGN secondary
to hepatitis B or C, autoimmune diseases such as lupus,
cryoglobulins, chronic bacterial infections, and monoclonal
gammopathy of unknown significance. LCMS identified
immunoglobulins in all cases although the type of immu-
noglobulin (IgG, IgA, IgM, Ig kappa light chains, Ig lambda
light chains, Ig heavy chains) varied reflecting the different
etiologies of IC-MPGN. C3 was the only complement factor
seen in all cases, although C4 was present in eight cases with
480% certainty. FHR1 was the next most frequently
identified protein. TCC complement factors and vitronectin
were rarely identified, and apoE was never seen (Figure 4;
Table 3).
DISCUSSION
DDD is characterized by amorphous electron-dense deposits
in the mesangium and along GBMs that stain for C3 by
immunofluorescence microscopy,1,2 and as expected, C3 was
present in glomeruli of all cases of DDD by LCMS. As
compared with both normal controls and IC-MPGN
glomeruli, DDD glomeruli had significantly more C5, C6,
C7, C8 (a, b, and g), vitronectin, and apoE (vitronectin—
95% protein prediction, Po0.05; remainder—80% protein
prediction probability, Po0.05). FHR5 was also only seen in
DDD glomeruli.
Proteins present in both DDD and IC-MPGN glomeruli
but absent in controls included FHR1, C4, clusterin, GBM-
Figure 3 | Protein identification by LCMS. (a) Representative scaffold readout of glomerular proteins for Case 4; (b) C5a identification by
peptide analysis; (c) Scaffold readout of proteins of interest in all eight cases of dense deposit disease and one control sample.
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specific heparan sulfate proteoglycan core protein precursor,
myosin 9, and some of the laminin subunits. Immuno-
globulin was uniquely present only in IC-MPGN samples.
Proteins found in all three types of glomeruli included
keratins, vimentin, collagen, actin, and histones.
Complement factors in DDD glomeruli
The AP is an important arm of innate immunity. Low level
auto-activity continuously occurs as a result of spontaneous
hydrolysis of a reactive thiolester on the a-chain of C3. This
process is known as ‘tick over’ and leads to the formation of
Figure 3 | Continued.
956 Kidney International (2009) 75, 952–960
o r i g i n a l a r t i c l e S Sethi et al.: Complement factors in Dense Deposit Disease
C3[H2O], which binds factor B to form C3[H2O]B. After
cleavage to C3[H2O]Bb by factor D, C3[H2O]Bb cleaves
additional C3 molecules to C3a and C3b. The C3b generated
by this process combines with factor B to form the AP C3
convertase, C3bBb.10,11
We detected both C3a and C3b chains in DDD glomeruli
by LCMS, a finding consistent with the structure of C3 as
single a and single b chains are joined by two disulfide
bonds.12 It is not possible by LCMS to determine whether the
detected peptides represent C3b or its breakdown products
iC3b, C3dg, or C3c, as we are analyzing trypsin digests.
Differentiating C3b from iC3b, C3dg, or C3c would be
valuable, as it could provide an indication of the site of
complement activation; however, factor B was not seen in any
DDD glomeruli. Its absence is noteworthy because both the
AP C3 convertase (C3bBb) and the C5 convertase
([C3b]Bb[C3b]) include factor B in their structures. These
convertases form on surfaces where AP activity is occurring,
suggesting that the major site of AP activity in DDD is not in
the glomeruli themselves but rather in the fluid phase.
The importance of fluid-phase activation of the AP in the
pathogenesis of DDD is supported by the work of Pickering
and colleagues who showed that factor I activity is an
absolute requirement for GBM C3 deposition in the Cfh/
mouse.13 The Cfh/ mouse typically develops glomerular
hypercellularity, mesangial expansion, and thickening of the
Table 3 | DDD versus IC-MPGN LCMS findings
Pathology
DDD (n=8) IC-MPGN (n=9)
Protein 495%a 480% 95% 480%
C3 8 8 6 7
C4 3 3 5 8
C5 7 7 1 1
C6 4 6 1 1
C7 1 4 0 0
C8a 3 5 0 0
C8b 2 7 0 0
C8g 2 5 0 0
C9 8 8 3 5
Immunoglobulin 0 0 9 9
FHR1 8 8 6 7
FHR5 1 2 0 0
Clusterin 8 8 4 6
Vitronectin 8 8 1 3
Apolipoprotein E 8 8 0 0
DDD, dense deposit disease; IC-MPGN, immune complex-mediated membranopro-
liferative glomerulonephritis; LCMS, liquid chromatography and mass spectrometry;
FHR, factor H-related protein.
aProtein prediction probability.
Figure 4 | Scaffold readout of proteins of interest for all nine cases of immune complex-mediated membranoproliferative
glomerulonephritis (MPGN). Clinical history is as follows: patient 1 was a case of hepatitis B; patient 2 had cryptogenic cirrhosis; patient 3
had an autoimmune disease with positive antinuclear antibodies and rheumatoid factor; patients 4 and 5 had no significant history and
likely had idiopathic MPGN type I; patient 6 had monoclonal gammopathy of unknown significance; patient 7 had cryoglobulins and a
questionable autoimmune disease; patient 8 likely had idiopathic MPGN type I; and patient 9 had chronic bacterial infections.
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capillary walls as seen by light microscopy. Electron
microscopy resolves the presence of subendothelial dense
capillary wall deposits and immunofluorescence shows
capillary wall and mesangial C3 staining.14 In the absence
of factor I (Cfh/.Cfi/ double mutant), capillary wall
C3 staining is not seen although mesangial hypercellularity
and C3 staining remain. This finding is consistent with the
dysregulation of fluid-phase AP convertase activity and
mesangial C3 production.13
DDD is frequently associated with the presence of C3
nephritic factor, which prolongs the half-life of C3 convertase
by protecting it from factor H-mediated decay.6,7 Consump-
tion of plasma C3 drives levels down and leads to the
formation of iC3b, C3dg, and C3c in the circulation. Our
findings and the work of Pickering and colleagues suggest
that it is these breakdown products of C3 that become
sequestered in the glomeruli.
We also found that TCC components C5, C6, C7, and C8
were specific for DDD. In the plasma, TCC activity is
controlled by complement regulatory proteins like
clusterin (SP-40, 40, cytolysis inhibitor, or ApoJ) and
vitronectin (S protein),15–17 both of which were present in
all DDD glomeruli. This observation is pertinent because
fluid-phase C5 convertase activity in DDD generates C5b,
which binds C6 and C7 to form C5b-7. Normally, the C5b-7
complex either inserts itself into a cell membrane or binds to
a single molecule of clusterin and vitronectin to form a
soluble C5b-7/clusterin/vitronectin complex. Once formed,
soluble C5b-7/clusterin/vitronectin complexes cannot
insert into a cell membrane; however, binding with C8 and
C9 can occur to produce inactive but soluble membrane
attack complex/clusterin/vitronectin (sMAC).15 Our
data suggest that sMAC becomes sequestered in DDD
glomeruli.
This observation implies that in addition to uncontrolled
activity of the AP in the fluid phase, DDD is also
characterized by excessive fluid-phase TCC production, with
sMAC accumulation in glomeruli. sMAC activates the
caspace pathway and apoptosis, and also causes transen-
dothelial migration of polymorphonuclear leucocytes,18,19
properties that could accelerate glomerular injury. Support-
ing this possibility, Pickering et al.20 have shown that the
DDD phenotype in Cfh/.C5/ double mutant mice is
characterized by lower mortality, decreased leucocyte infil-
tration, and a reduction in serum creatinine when compared
with the phenotype observed in Cfh/ mutants. Surpris-
ingly, however, in Cfh/.C6/ double mutants, there was
no change in disease severity when compared with Cfh/
mutants, a finding these investigators interpreted to mean
that C5a is more important than the TCC in the pathogenesis
of DDD. Alternatively, however, it is possible that some
protein–protein interactions within sMAC occur in the
absence of C6. In the fluid-phase, C6 and C7 mediate
reversible binding to C5 and bound C6 is easily displaced by
C7. Only the reaction between C5 and the C7 factor I
modules are important for MAC assembly.21
Factor H-related proteins in DDD and IC-MPGN glomeruli
The most important fluid-phase regulator of the AP is factor
H.10 This protein is composed of 20 short consensus repeats
(SCRs), each of which approximates 60 amino acids, with
neighboring SCRs joined by short 6–12 amino acid linkers.
The SCRs differ in amino acid sequence, imparting to factor
H multiple SCR-specific functions. Factor H-like 1, a splice
variant of the factor H gene, consists of 7 SCRs that are
identical to the first 7 N-terminal SCRs of factor H and a
C-terminus that includes 4 additional amino acids encoded
by a unique exon that includes a stop codon and unique
untranslated 30 end. Also included in the factor H family are
five factor H-related proteins encoded by distinct genes
(CFHR1-5).22
We detected FHR1 in all DDD glomeruli and seven of nine
IC-MPGN glomeruli; FHR5 was present in two DDD
glomeruli (480% certainty). The first finding suggests that
FHR1 may play a non-specific role in C3-associated
glomerulonephritis. FHR1 is comprised of five SCRs, the
last three of which are nearly identical to SCRs 18, 19, and 20
of factor H. (There is a two amino acid difference in SCR5 of
FHR1.) This degree of similarity with SCRs 18, 19, and 20 of
factor H is not seen in any other FRH protein.22 SCRs 1–2 of
FHR-1 are most similar to SCRs 6 and 7 of factor H and,
therefore, may have some endothelial cell and heparin
binding affinity.23 Because FHR1 lacks SCRs with similarity
to SCRs1–4 of factor H, it is not predicted to have major
complement regulatory activity22 (Figure 5).
The GBM lacks intrinsic regulators of AP activation and
sequesters factor H in small quantities from the serum.24
The two terminal SCRs of factor H are essential for
binding to the GBM25 and distinguishing between activator
surfaces (those surfaces that activate the complement
cascade) and nonactivator surfaces.26 Ferreira and colleagues
demonstrated their importance by showing that a small
recombinant protein composed of only SCRs 19 and 20 of
factor H (rH19-20) inhibits regulatory activities of factor H
FHR-1 1 2 3 4 5
6 7 18 19 20
Factor H





Figure 5 | Comparison of the SCRs of factor H with those of
FHR1. FHR1 is comprised of five SCRs. The last three SCRs have
nearly 100% identity with SCRs 18, 19, and 20 of factor H and are
shown in blue. SCRs 1 and 2 of FHR1 have modest identity with
SCRs 6 and 7 of factor H, hence the slightly different colors. SRC,
short consensus repeat; FHR1, factor H-related protein 1; GBM,
glomerular basement membrane.
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toward cell-bound C3b, and by out-competing factor H for
binding sites, causes aggressive complement-mediate lysis of
nonactivating sheep erythrocytes.26 Even partial lysis of
human erythrocytes was observed, which is significant
as human erythrocytes have both CD55 and CD59 on
their surface.
It is possible, therefore, that FHR1 may bind to the GBM
in a variety of complement-mediated and immune complex-
mediated glomerular diseases. Whether its presence is
harmful, protective, or an epiphenomenon is unclear. The
possible function of FHR5 in DDD glomeruli is not known,
although mutations in this gene have been identified in a few
affected patients.27
Apolipoprotein E
ApoE is a 299-amino acid polymorphic glycoprotein. Its three
common alleles, A2, A3, and A4, code for E2, E3, and E4 to
determine the phenotypes E2/E2, E3/E3, E4/E4, E2/E3, E2/E4,
and E3/E4.28–31 The liver is the primary site of synthesis and in
the circulation apoE plays a major role in lipoprotein
clearance.32,33 An important secondary site of synthesis is the
mesangial cell, and in the kidney apoE has an autocrine
function to mediate uncontrolled mesangial expansion and to
regulate heparan sulfate glycoprotein levels.34 The A3 allele is
most effective in inhibiting mesangial cell proliferation.34
Although several studies have identified associations between
apoE polymorphisms and nephropathy,35–38 the significance of
the presence of apoE in DDD glomeruli has not been explored.
Conclusion
This study used LCMS to identify proteins in DDD glomeruli.
Findings were compared with normal controls and to biopsies
of IC-MPGN and suggest that fluid-phase dysregulation of both
the AP and the TCC contributes to the glomerular pathology
that is seen in DDD. ApoE was also uniquely seen in DDD
glomeruli, although the significance of this finding is unclear.
FHR1 was seen in both DDD and IC-MPGN glomeruli and




Between January 2006 and September 2007, renal biopsies from
eight patients demonstrating DDD were evaluated. These biopsies
were cases sent to the Mayo Clinic for interpretation and diagnosis.
Normal-appearing glomeruli from five cases of living-related Day 0
protocol transplant biopsies were used as control samples. We also
analyzed renal biopsies from nine cases of IC-MPGN. The
Institutional Review Board at the Mayo Clinic approved the use of
these biopsies on the basis that identifying information on each
patient would remain unknown.
Specimen preparation and microdissection
10 mm-thick sections of formalin-fixed paraffin-embedded tissues
were placed on DIRECTORTM slides (Expression Pathology,
Gaithersburg, MD, USA) for laser microdissection. Sections were
air-dried, melted, and deparaffinized, and an H&E stain was
performed on all samples. Two glomeruli were photographed and
then microdissected into 0.5 ml microcentrifuge tube caps contain-
ing 35 ml Tris/EDTA/0.002% Zwittergent 3–16 buffer using a Leica
DM6000B Microdissection System. The method was repeated with a
second slide and again two glomeruli were microdissected.
Glomeruli with global sclerosis or extensive segmental sclerosis
were not selected for microdissection. Collected tissues were heated
at 981C for 90 min with occasional vortexing. Following 30 min of
sonication in a waterbath, samples were reduced DTT, alkylated with
iodoacetamide, digested overnight at 371 with 1.5ml 1 ug/ml trypsin
(Promega, Madison, WI, USA).
Protein identification via mass spectrometry
The trypsin-generated digests were used for protein identification by
nano-flow liquid chromatography electrospray tandem mass
spectrometry using a ThermoFinnigan LTQ Orbitrap Hybrid Mass
Spectrometer (ThermoElectron Bremen, Germany) coupled to an
Eksigent nanoLC-2D HPLC system (Eksigent, Dublin, CA, USA), as
described previously.39
The peptide mixtures were injected onto a magic C18 packed
0.25ml trap (Optimize Technologies) packed with Michrom 5 mm
C18 plumbed into a 10-port valve. The peptides were then eluted
onto a 75 mm 10 cm column packed with 5 mm Michrom C18 and
eluted with a 400 nl/min 60 min organic gradient (5–55% ACN in
0.1% formic acid).
The mass spectrometer was operated in the data-dependent
mode to automatically switch between orbitrap-MS and iontrap-
MS/MS (MS2) acquisition. Survey full scan MS spectra (from m/z
375–1800) were acquired in the orbitrap with resolution 60,000 at
m/z 400 (after accumulation to a target value of 1,000,000 charges in
the linear ion trap). The most intense ions (up to five, depending on
signal intensity) were sequentially isolated for fragmentation in the
linear ion trap using collisionally induced dissociation at a target
value of 100,000 charges. The resulting fragment ions were recorded
in the orbitrap with a resolution of 15,000 at m/z 400. For accurate
mass measurements, the lock mass option was enabled in both MS
and MS/MS mode, and the polydimethylcyclosiloxane ions gener-
ated in the electrospray process from ambient air (protonated
(Si(CH3)2O))6; m/z _ 445.120025) were used for internal
recalibration in real time.40 Target ions already selected for MS/
MS were dynamically excluded for 30 s. General mass spectrometric
conditions were electrospray voltage, 2.2 kV; no sheath and
auxiliary gas flow; ion transfer tube temperature, 2001C;
collision gas pressure, 1.3 mT; normalized collision energy, 32%
for MS2. Ion selection threshold was 100 counts for MS2. An
activation q of 0.25 and activation time of 30 ms was applied for
MS2 acquisitions.
Criteria for protein identification
An in-house developed workflow tool (SWiFT) was utilized to
search ThermoFisher raw data files. This tool parses the raw data file
to Sequest, Mascot, and X!Tandem search engines. The results are
combined and assigned peptide and protein probability scores in
Scaffold (version Scaffold-01_07_00, Proteome Software Inc.,
Portland, OR, USA). Peptide identifications were accepted if they
could be established at greater than 90.0% probability as specified by
the Peptide Prophet algorithm.41 Protein identifications were
accepted if they could be established at greater than 95% probability
and contained at least two identified peptide. Protein probabilities
were assigned by the Protein Prophet algorithm.41,42
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